Recently released market study: AstraZeneca plc: PharmaVitae Profile

Recently published research from Datamonitor, "AstraZeneca plc: PharmaVitae Profile", is now available at Fast Market Research
Spread the Word
Listed Under



Massachusetts - US

May 16, 2011 - PRLog -- Introduction

This analysis examines the historical and forecast performance for AstraZeneca in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs.
Features and benefits

* Gain insight into AstraZeneca's strategic outlook across the next 6 years.* Analyze company sales forecasts by product, therapy area, lifecycle stage, geography, molecule type and source.


Strategic insight into the prospects for AstraZeneca over the next six years. Picking out key strengths, weaknesses, opportunities and threats and evaluating the company's prescription pharmaceuticals outlook using a variety of cuts of the historical and forecast sales.
Your key questions answered

Full Report Details at

* Benchmark AstraZeneca's performance against key rivals in the prescription pharmaceutical sector.* Assess the importance of Crestor, set to become the industry's biggest selling product, to AstraZeneca's forecast growth performance.* Analyse AstraZeneca's high level of anticipated exposure to flagship product patent expiries through to 2015 and the impact on company strategy.

Partial Table of Contents:

About Datamonitor Healthcare
About the PharmaVitae team
Chapter 1 About this profile
PharmaVitae Explorer database
Chapter structure
Data sourcing
Chapter 2 Executive summary
Key findings
Prescription pharmaceutical sales and growth rate performance, 2003-15
Financial performance, 2003-15
AstraZeneca: PharmaVitae forecasts at a glance
Strategic insight
SWOT analysis
Chapter 3 Quarterly update
Latest quarterly sales
Latest quarterly financial analysis
Latest comment
Latest prescription pharma product news
Latest corporate news
Future product milestones
Chapter 4 Company introduction
Key findings
M&A history
Chapter 5 Company sales
Key findings
Prescription pharmaceutical sales and growth rate analysis, 2003-15
Product analysis
Therapy area analysis
Geographic analysis
Launch/core/expiry analysis
Molecule type analysis
Externalization analysis
Chapter 6 Company financials
Key findings
Reconciliation between PharmaVitae-formatted prescription pharma sales and company-reported total sales, 2003-09
Operating costs and profit analysis
Chapter 7 Key products
Seloken/Toprol XL
Chapter 8 Appendix
Exchange rates
About Datamonitor
Datamonitor consulting

Table 1: AstraZeneca - PharmaVitae forecasts at a glance
Table 2: AstraZeneca quarterly sales, Q309-Q310
Table 3: AstraZeneca quarterly financials ($m), Q309-Q310
Table 4: AstraZeneca future product milestones, 2010-12
Table 5: AstraZeneca product portfolio overview ($m), 2003-09
Table 6: AstraZeneca product portfolio overview ($m), 2009-15
Table 7: AstraZeneca prescription pharmaceutical sales by therapy area ($m), 2009-15
Table 8: AstraZeneca prescription pharmaceutical sales by geographic region ($m), 2009-15
Table 9: AstraZeneca launch portfolio overview ($m), 2009-15
Table 10: AstraZeneca core portfolio overview ($m), 2009-15
Table 11: AstraZeneca expiry portfolio overview ($m), 2009-15
Table 12: AstraZeneca prescription pharmaceutical sales by molecule type ($m), 2009-15
Table 13: AstraZeneca prescription pharmaceutical sales by source ($m), 2009-15
Table 14: Total AstraZeneca sales by business unit ($m), 2003-09
Table 15: AstraZeneca operating revenue/cost analysis ($m), 2003-09
Table 16: AstraZeneca operating cost ratio analysis (% of total revenues), 2003-09
Table 17: AstraZeneca operating cost ratio analysis (% of total revenues), 2008-14
Table 18: AstraZeneca operating revenue/cost analysis ($m), 2009-15
Table 19: AstraZeneca key products overview
Table 20: Crestor: overview
Table 21: Crestor: sales forecast ($m), 2009-15
Table 22: Brilinta: overview
Table 23: Brilinta: sales forecast ($m), 2009-15
Table 24: Onglyza: overview
Table 25: Onglyza: sales forecast ($m), 2009-15
Table 26: Certriad: overview
Table 27: Certriad: sales forecast ($m), 2009-15
Table 28: Dapagliflozin: overview
Table 29: Dapagliflozin: sales forecast ($m), 2009-15
Table 30: Seroquel: overview
Table 31: Seroquel: sales forecast ($m), 2009-15
Table 32: Nexium: overview
Table 33: Nexium: sales forecast ($m), 2009-15
Table 34: Seloken/Toprol XL: overview
Table 35: Seloken/Toprol XL: sales forecast ($m), 2009-15
Table 36: Pulmicort: overview
Table 37: Pulmicort: sales forecast ($m), 2009-15
Table 38: Arimidex: overview
Table 39: Arimidex: sales forecast ($m), 2009-15
Table 40: Exchange rates, 2010

Figure 1: The PharmaVitae Explorer
Figure 2: AstraZeneca prescription pharmaceutical performance, sales ($m) and growth rate (%), 2003-15
Figure 3: AstraZeneca's financial performance ($m), 2003-15
Figure 4: AstraZeneca prescription pharmaceutical sales by launch/core/expiry classification ($m), 2009-15
Figure 5: AstraZeneca's prescription pharmaceutical sales growth by portfolio component (blockbusters, rest of portfolio, new launches) ($m), 2003-15

Full Table of Contents is available at:

About Datamonitor

The Datamonitor Group is a world-leading provider of premium global business information, delivering independent data, analysis and opinion across the Automotive, Consumer Markets, Energy & Utilities, Financial Services, Logistics & Express, Pharmaceutical & Healthcare, Retail, Technology and Telecoms industries. Datamonitor's market intelligence products and services ensure that you will achieve your desired commercial goals by giving you the insight you need to best respond to your competitive environment.  View more research from Datamonitor at

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at or call us at 1.800.844.8156.

# # #

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.
Email:*** Email Verified
Tags:Astrazeneca, Prescription, Pharmaceutical, 2003-15, Pharmavitae, 2003-09, Revenuecost, Crestor, Molecule, Therapy
Industry:Medical, Research, Biotech
Location:Massachusetts - United States
Account Email Address Verified     Account Phone Number Verified     Disclaimer     Report Abuse
Fast Market Research PRs
Trending News
Top Daily News
Top Weekly News

Like PRLog?
Click to Share